Mavacamten in Obstructive Hypertrophic Cardiomyopathy – Are Beta-Blockers blocking Part of its Shine?
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2768 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Fernando Dominguez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Heart Failure, Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
This article refers to 'Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy' by M.T. Wheeler et al., published in this issue on pages 260-270.Nowadays, targeted therapies are emerging in the field of genetic cardiomyopathies.In the coming years, generic treatments and one fits all-based strategies will be hopefully replaced by treatments that focus on pathophysiological bases of disease.[1][2][3] The increasing knowledge of the genetic aetiologies and signalling pathways in cardiomyopathies explain the burst of interest in tailored therapies.Furthermore, thanks to multicentre and collaborative efforts by the medical community, we are reaching aetiological diagnoses more frequently and we are establishing genotype-phenotype correlations that will benefit patients with cardiomyopathies and their families.Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease.Its prevalence has been reported to range from 1:200 to 1:500 individuals and it is predominantly inherited in an autosomal dominant manner.HCM is associated with excessive cardiac myosin-actin cross-bridging 4 that result in hypercontractility, together with left ventricular hypertrophy and reduced left ventricular compliance.Left ventricular outflow obstruction (LVOTO), either at rest or with provocative manoeuvres, is present in almost 70% of patients with HCM.LVOTO is associated with impaired stroke volume and an increased risk of heart failure, as well as poorer survival.5 The main role of pharmacologic LVOTO therapy is symptom relief, and until recently, obstructive HCM (oHCM) treatment has been limited to beta-blockers or non-dihydropyridine calcium channel blockers (CCB), with disopyramide as a second-line agent.Back in 2020, the double-blind, randomized, placebo-controlled phase 3 EXPLORER-HCM trial 6 highlighted the benefits of a newThe opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Madrid, Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
ORCID-Profile: Fernando Dominguez
Zitieren
APA
Dominguez, F., & Cabrera, E. (2023). Mavacamten in Obstructive Hypertrophic Cardiomyopathy – Are Beta-Blockers blocking Part of its Shine?. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2768
Vancouver
Dominguez F, Cabrera E. Mavacamten in Obstructive Hypertrophic Cardiomyopathy – Are Beta-Blockers blocking Part of its Shine?. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2768
BibTeX
@article{Dominguez2023,
author = {Dominguez, Fernando and Cabrera, Eva},
title = {Mavacamten in Obstructive Hypertrophic Cardiomyopathy – Are Beta-Blockers blocking Part of its Shine?},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2768}
}
EUVIMED